U.S. Markets open in 8 hrs 25 mins
  • S&P Futures

    4,065.00
    -10.50 (-0.26%)
     
  • Dow Futures

    34,009.00
    -14.00 (-0.04%)
     
  • Nasdaq Futures

    12,041.75
    -65.00 (-0.54%)
     
  • Russell 2000 Futures

    1,906.40
    -4.10 (-0.21%)
     
  • Crude Oil

    81.40
    +0.39 (+0.48%)
     
  • Gold

    1,924.60
    -5.40 (-0.28%)
     
  • Silver

    23.92
    -0.10 (-0.44%)
     
  • EUR/USD

    1.0878
    -0.0014 (-0.1305%)
     
  • 10-Yr Bond

    3.4930
    0.0000 (0.00%)
     
  • Vix

    18.73
    -0.35 (-1.83%)
     
  • GBP/USD

    1.2378
    -0.0029 (-0.2315%)
     
  • USD/JPY

    129.9450
    -0.2080 (-0.1598%)
     
  • BTC-USD

    23,025.25
    -142.76 (-0.62%)
     
  • CMC Crypto 200

    521.37
    -5.82 (-1.10%)
     
  • FTSE 100

    7,761.11
    +16.24 (+0.21%)
     
  • Nikkei 225

    27,380.32
    +17.57 (+0.06%)
     

HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

Renowned Stanford Cardiologist Brings Deep Clinical, Research, and Industry Expertise to Executive Team

SANTA CLARA, Calif., October 11, 2022--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced the appointment of Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer. In addition to his world-renowned expertise in interventional cardiology, Dr. Fitzgerald is an accomplished inventor, entrepreneur, and investment fund founder.

"We are thrilled to have Dr. Fitzgerald, one of the world’s preeminent opinion leaders in cardiology and digital health, join the HeartBeam leadership team and play a major role in defining best paths to adoption, clinical strategies, and partnerships to advance our products in the market," said Branislav Vajdic, PhD, founder and CEO of HeartBeam. "In addition to his cardiovascular clinical and research expertise, Dr. Fitzgerald has a rich history of developing successful collaborations with partners in the industry and has developed deep connections across the investment and medical communities."

About Peter J. Fitzgerald, MD, PhD

Dr. Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is an interventional cardiologist and holds a PhD in electrical engineering. Dr. Fitzgerald is Professor Emeritus in the Departments of Medicine (Cardiology) at Stanford University and has led or participated in over 175 clinical trials, published over 650 manuscripts/chapters, and lectures worldwide. Over the past two decades, he has trained over 150 post-doctoral candidates in engineering and medicine. Dr. Fitzgerald has been principle and founder of 24 medical device companies in the San Francisco Bay area, transitioning 18 of these start-ups to medium/large-cap life science companies. In 2009, he co-founded TriVentures, an Israeli-based incubator/venture fund for early-stage medical technology and digital health. He has also been a consultant to the US Food and Drug Administration for the past 20 years, focused on medical technology and data driven health analytics.

"HeartBeam’s focus on bringing novel diagnostic tools to cardiac patients, especially those with a high risk for a heart attack, could have a significant, positive impact on medical outcomes and quality of life for patients while potentially saving healthcare dollars," said Dr. Fitzgerald. "I look forward to supporting the planned advancement of the Company’s rich product pipeline to deliver comprehensive cardiac care for patients anytime, anywhere."

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005625/en/

Contacts

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

Media Contact:
Capwell Communications
media@capwellcomm.com
949-999-3303